C Kollmannsberger1, S Tyldesley2, C Moore3, K N Chi1, N Murray1, S Daneshmand4, P Black5, G Duncan2, B Hayes-Lattin6, C Nichols7. 1. Division of Medical Oncology, Department of Medicine. 2. Division of Radiation Oncology, Department of Surgery, British Columbia Cancer Agency/University of British Columbia, Vancouver Cancer Centre, Vancouver, Canada. 3. Earle A Chiles Research Institute, Providence Cancer Center, Portland. 4. Institute of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, USA. 5. Department of Urological Sciences, UBC, The Prostate Centre at Vancouver General Hospital, Vancouver, Canada. 6. Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University Knight, Cancer Institute, Portland, USA. 7. Earle A Chiles Research Institute, Providence Cancer Center, Portland. Electronic address: craig.nichols@providence.org.
Abstract
BACKGROUND: In this article, we report the evolution of treatment with increased use of active surveillance for stage I disease as well as risk-adapted chemotherapy for disseminated disease and associated outcomes of testicular seminoma in a contemporary population-based cohort. METHODS: All patients with histologically confirmed seminoma referred from 1999 to 2008 to the British Columbia Cancer Agency or Providence Cancer Center were retrospectively reviewed. Both institutions manage 90% of testicular cancers in their respective area. RESULTS: A total of 649 patients were included. Clinical stage (CS) distribution: CSI/II/III n=545/87/17. For CSI, there was a progressive and marked decrease in the utilization of prophylactic radiation (RT), and corresponding increase in the use of active surveillance. No deaths related to seminoma were reported in CSI patients. CSII or CSIII patients received RT or International Germ Cell Cancer Collaborative Group (IGCCCG) risk-appropriate chemotherapy with 101 of 104 patients being in long-term remission and 3 patients dying from treatment complications. For the entire seminoma population, <1% of patients died of seminoma or treatment after a median follow-up of 47 months (range 2-130 months). CONCLUSIONS: Progressive application of policies of active surveillance and earlier initiation of IGCCCG risk-adapted chemotherapy result in nearly universal control for all patients presenting with seminoma while reducing the burden of treatment.
BACKGROUND: In this article, we report the evolution of treatment with increased use of active surveillance for stage I disease as well as risk-adapted chemotherapy for disseminated disease and associated outcomes of testicular seminoma in a contemporary population-based cohort. METHODS: All patients with histologically confirmed seminoma referred from 1999 to 2008 to the British Columbia Cancer Agency or Providence Cancer Center were retrospectively reviewed. Both institutions manage 90% of testicular cancers in their respective area. RESULTS: A total of 649 patients were included. Clinical stage (CS) distribution: CSI/II/III n=545/87/17. For CSI, there was a progressive and marked decrease in the utilization of prophylactic radiation (RT), and corresponding increase in the use of active surveillance. No deaths related to seminoma were reported in CSI patients. CSII or CSIII patients received RT or International Germ Cell Cancer Collaborative Group (IGCCCG) risk-appropriate chemotherapy with 101 of 104 patients being in long-term remission and 3 patients dying from treatment complications. For the entire seminoma population, <1% of patients died of seminoma or treatment after a median follow-up of 47 months (range 2-130 months). CONCLUSIONS: Progressive application of policies of active surveillance and earlier initiation of IGCCCG risk-adapted chemotherapy result in nearly universal control for all patients presenting with seminoma while reducing the burden of treatment.
Authors: Christian G Ruf; Stefanie Schmidt; Sabine Kliesch; Christoph Oing; David Pfister; Jonas Busch; Julia Heinzelbecker; Christian Winter; Friedemann Zengerling; Peter Albers; Karin Oechsle; Susanne Krege; Julia Lackner; Klaus-Peter Dieckmann Journal: World J Urol Date: 2022-09-15 Impact factor: 3.661
Authors: Robert J Hamilton; Christina Canil; Noa Shani Shrem; Kopika Kuhathaas; Maria Di Jiang; Peter Chung; Scott North; Piotr Czaykowski; Sebastien Hotte; Eric Winquist; Christian Kollmannsberger; Armen Aprikian; Denis Soulières; Scott Tyldesley; Alan I So; Nicholas Power; Ricardo A Rendon; Martin O'Malley; Lori Wood; Michael A S Jewett Journal: Can Urol Assoc J Date: 2022-06 Impact factor: 2.052
Authors: Gregory J Nason; Ricardo A Rendon; Lori Wood; Robert A Huddart; Peter Albers; Lawrence H Einhorn; Craig R Nichols; Christian Kollmannsberger; Lynn Anson-Cartwright; Padraig Warde; Michael A S Jewett; Peter Chung; Philippe L Bedard; Aaron R Hansen; Robert J Hamilton Journal: Can Urol Assoc J Date: 2021-01 Impact factor: 1.862
Authors: Bishal Gyawali; Rebecca Griffiths; Andrew G Robinson; Matthew D F McInnes; Philippe L Bedard; Christopher M Booth Journal: Can Urol Assoc J Date: 2022-02 Impact factor: 2.052
Authors: C G Ruf; H-U Schmelz; M Port; W Wagner; C Matthies; B Müller-Myhsok; V Meineke; M Abend Journal: Br J Cancer Date: 2014-05-01 Impact factor: 7.640
Authors: Christian G Ruf; Daniela Dinger; Matthias Port; Hans-Ulrich Schmelz; Walter Wagner; Cord Matthies; Bertram Müller-Myhsok; Viktor Meineke; Michael Abend Journal: Mol Cancer Date: 2014-03-06 Impact factor: 27.401